Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 1;13(1):e2021006.
doi: 10.4084/MJHID.2021.006. eCollection 2021.

Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature

Affiliations
Review

Socioeconomic Status is Globally a Prognostic Factor for Overall Survival of Multiple Myeloma Patients: Synthesis of Studies and Review of the Literature

Stergios Intzes et al. Mediterr J Hematol Infect Dis. .

Abstract

Background: Socioeconomic status (SES) is reflecting differences in sociodemographic factors affecting cancer survivorship. Deprived, low SES populations have a higher prevalence of multiple myeloma and worst survival, a condition which widens over time.

Methods: We performed a meta-analysis of 16 studies (registries and cohorts) reporting myeloma patients' survival data according to SES. Ten studies reported Hazzard Ratio (H.R.) (95 % CI), and 16 studies reported p values. We combined the H.R. from 10 studies, and by using the Mosteller-Bush formula, we performed a synthesis of p values according to the area of the globe.

Results: Combination of H.R. from 10 studies including 85198 myeloma patients weighted to sample size of each study and adopting the hypothesis of random effect returned a combined H.R.: 1,26 (1,13-1,31) in favor of high SES patients.USA: Synthesis of p values coming from 6 studies (n=89807 pts) by using the Mosteller and Bush formula extracted a p-value of <0.0001 favoring high SES patients.Oceania: Synthesis of p values in two cohorts from Australia and New Zealand (n= 10196 pts) returned a p-value of 0,022 favoring high SES patients.Europe: The synthesis of p values from the U.K. and Greece studies (n=18533 pts) returned a p-value of <0,0001 favoring high SES patients.Asia: Synthesis of 2 studies from Asia (n=915 pts) returned a p-value of <0,0001 favoring high SES patients.

Conclusions: Across the globe and widening over decades, the socioeconomic status remains a gap for equality in myeloma care.

Keywords: Myeloma; Socioeconomic status.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no conflict of Interest.

Figures

Figure 1
Figure 1
Myeloma care according to ethnicity/race in East Macedonia and Thrace Greece. A) Disease characteristics and therapy with new anti-myeloma agents or autologous stem cell transplantation (ASCT) in Greeks and Greek Muslims. B) Progression Free Survival after first line treatment according to ethnicity/race (PFS1).
Figure 2
Figure 2
Studies flow diagram and final selection of studies included in this meta-analysis.
Figure 3
Figure 3
A) Meta-analysis and combination of Hazzard Ratio (H.R.) extracted from 10 studies reporting H.R. (95 % CI) for overall survival (O.S.) according to socioeconomic status (SES). B) Synthesis of p values from 16 studies reporting H.R. (95 % CI) for O.S. at 5 years according to SES segregating according to area of the globe that data are coming from. In each table percentage of 5y O.S. from all studies is reported and p values on the top denotes synthesis of p from all studies in this part of the world.

Similar articles

Cited by

References

    1. Fonseca R, Hinkel J. Value and Cost of Myeloma Therapy-We Can Afford It. Am Soc Clin Oncol Educ Book. 2018;38:647–655. doi: 10.1200/EDBK_200869. - DOI - PubMed
    1. Kumar L, Cyriac SL, Tejomurtula TV, et al. Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors. Clin Lymphoma Myeloma Leuk. 2013;13:32–41. doi: 10.1016/j.clml.2012.08.007. - DOI - PubMed
    1. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52–iv61. doi: 10.1093/annonc/mdx096. - DOI - PubMed
    1. Ailawadhi S, Bhatia K, Aulakh S, et al. Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet? Curr Hematol Malig Rep. 2017;12:309–316. doi: 10.1007/s11899-017-0393-y. - DOI - PubMed
    1. Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia. 2012;26:609–614. doi: 10.1038/leu.2011.368. - DOI - PMC - PubMed